Biogen has made an unsolicited offer to acquire its partner Sage Therapeutics following a year of significant challenges for the latter. The deal, which values Sage at $7.22 per share, represents ...

Sage Therapeutics (SAGE) said Biogen (BIIB) has made an unsolicited offer to acquire the rest of SAGE shares. Biogen currently owns a 10.2% stake in Sage Therapeutics; SAGE board members will ...

Sage Therapeutics and Biogen's antidepressant candidate zuranolone has hit its objectives in a phase 3 trial, but a falloff in efficacy over time has raised concerns about the commercial potential ...

Sage Therapeutics (NASDAQ:SAGE) traded lower for the third straight session on Tuesday after Bank of America moved the stock’s rating to Underperform, noting that the impact of Biogen’s ...

BofA resumed coverage of Sage Therapeutics (SAGE) with an Underperform rating and $5 price target. The impact of Biogen’s (BIIB) unsolicited takeover has now passed, and in the absence of clear ...

Sage Therapeutics and partner Biogen equally shares profits and losses for the commercialization of Zurzuvae in the United States. In ex-U.S. markets, Biogen records product sales (excluding Japan ...

January 27, 2025 Sage rejects Biogen's $469 million takeover offer, says offer undervalues company Sage Therapeutics said on Monday that its board has unanimously rejected Biogen’s $469 million ...

Farmer covers the Healthcare sector, focusing on stocks such as SAGE Therapeutics, Kura Oncology, and Biomea Fusion. In addition to Scotiabank, Biogen also received a Buy from Canaccord Genuity ...